2023 CMTA Annual Report
Fall_2020_CMTA_Report
CMTA 2023 Annual Report Download
Keep Hope Alive for Everyone Living with CMT
…$10,000 donation could be used to fund biomarker research to enable clinical trials for CMT1A, CMT2A, CMT1B, CMT1X. There are many ways for your donation to accelerate research. As you…
CMTA 2023 Annual Report
CMTAWinter2021Report
CMTAreportSummer2023spreads
SYNAPSE-CMT: Join the Journey to Advance CMT Research
SYNAPSE-CMT Clinical Trial What is the SYNAPSE-CMT Clinical Trial? CMTA-STAR Alliance Partner NMD Pharma has recently started screening and enrolling patients in the SYNAPSE-CMT Phase II trial. This trial aims…
Hearing Loss and CMT
…(28.2% and 30%, respectively). Other CMT subtypes associated with hearing loss include hereditary neuropathy with liability to pressure palsies (HNPP), CMT1X, and CMT2A. CMT-related hearing loss usually affects both ears…
What is CMTA-STAR?
…– CMT1A, CMT2A, CMT2E, CMT1X, CMT1B and CMT4.) Advanced team efforts take place in consortia involving multiple partners with expertise in assay development, high-throughput screening, animal model development, pharmacology, medicinal…